CN107375285A - 基于阿拉莫林的药物治疗 - Google Patents

基于阿拉莫林的药物治疗 Download PDF

Info

Publication number
CN107375285A
CN107375285A CN201710646685.0A CN201710646685A CN107375285A CN 107375285 A CN107375285 A CN 107375285A CN 201710646685 A CN201710646685 A CN 201710646685A CN 107375285 A CN107375285 A CN 107375285A
Authority
CN
China
Prior art keywords
anamorelin
patient
cancer
patients
cachexia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710646685.0A
Other languages
English (en)
Chinese (zh)
Inventor
威廉·曼
约翰·弗兰德
威廉·波尔维诺
苏珊·艾伦
陆明
伊丽莎白·杜斯
鲁本·焦尔吉诺
恩里科·布洛尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107375285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Publication of CN107375285A publication Critical patent/CN107375285A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201710646685.0A 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗 Pending CN107375285A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
US62/045,976 2014-09-04
CN201580059744.3A CN107205389A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580059744.3A Division CN107205389A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗

Publications (1)

Publication Number Publication Date
CN107375285A true CN107375285A (zh) 2017-11-24

Family

ID=55436476

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201710646685.0A Pending CN107375285A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN201580059744.3A Pending CN107205389A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN202111027023.8A Pending CN113577074A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN202111026050.3A Pending CN113577073A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN201811119404.7A Pending CN109172575A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201580059744.3A Pending CN107205389A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN202111027023.8A Pending CN113577074A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN202111026050.3A Pending CN113577073A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN201811119404.7A Pending CN109172575A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗

Country Status (44)

Country Link
US (5) US9675600B2 (cg-RX-API-DMAC7.html)
EP (2) EP3590338A3 (cg-RX-API-DMAC7.html)
JP (3) JP6356907B2 (cg-RX-API-DMAC7.html)
KR (3) KR102234319B1 (cg-RX-API-DMAC7.html)
CN (5) CN107375285A (cg-RX-API-DMAC7.html)
AP (1) AP2017009772A0 (cg-RX-API-DMAC7.html)
AR (1) AR103118A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015312231B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017003552A2 (cg-RX-API-DMAC7.html)
CA (1) CA2959158A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000494A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017003263A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170121A (cg-RX-API-DMAC7.html)
CY (1) CY1122746T1 (cg-RX-API-DMAC7.html)
DK (1) DK3188599T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000055A (cg-RX-API-DMAC7.html)
EA (1) EA035578B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17019893A (cg-RX-API-DMAC7.html)
ES (1) ES2761777T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20186939B (cg-RX-API-DMAC7.html)
HR (1) HRP20192345T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046894T2 (cg-RX-API-DMAC7.html)
IL (1) IL250692B (cg-RX-API-DMAC7.html)
JO (1) JO3541B1 (cg-RX-API-DMAC7.html)
LT (1) LT3188599T (cg-RX-API-DMAC7.html)
MA (1) MA40607B1 (cg-RX-API-DMAC7.html)
MD (1) MD4710C1 (cg-RX-API-DMAC7.html)
ME (1) ME03597B (cg-RX-API-DMAC7.html)
MX (1) MX361741B (cg-RX-API-DMAC7.html)
MY (1) MY187167A (cg-RX-API-DMAC7.html)
NI (1) NI201700024A (cg-RX-API-DMAC7.html)
PE (1) PE20171109A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500392B1 (cg-RX-API-DMAC7.html)
PL (1) PL3188599T3 (cg-RX-API-DMAC7.html)
PT (1) PT3188599T (cg-RX-API-DMAC7.html)
RS (1) RS59751B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701567UA (cg-RX-API-DMAC7.html)
SI (1) SI3188599T1 (cg-RX-API-DMAC7.html)
SV (1) SV2017005400A (cg-RX-API-DMAC7.html)
TN (1) TN2017000040A1 (cg-RX-API-DMAC7.html)
TW (1) TWI639429B (cg-RX-API-DMAC7.html)
UA (1) UA120765C2 (cg-RX-API-DMAC7.html)
UY (1) UY36286A (cg-RX-API-DMAC7.html)
WO (1) WO2016036598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
JP7854809B2 (ja) 2019-08-30 2026-05-07 ヘルシン ヘルスケア ソシエテ アノニム 安定性が改善されたアナモレリン錠剤の製造方法
AU2020372131B2 (en) * 2019-10-24 2025-10-30 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
JPWO2025004650A1 (cg-RX-API-DMAC7.html) * 2023-06-28 2025-01-02

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
JP2007523048A (ja) * 2003-08-06 2007-08-16 ガストロテック・ファルマ・アクティーゼルスカブ 分泌促進物質の使用
US20050261201A1 (en) 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
EP2854810A4 (en) * 2012-05-25 2016-04-06 Raqualia Pharma Inc GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURROW DC等: "Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome", 《FUTURE ONCOLOGY》 *
JM GARCIA等: "Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study", 《CANCER & METABOLISM》 *
林丽珠: "《肿瘤中西医治疗学》", 30 September 2013, 人民军医出版社 *

Also Published As

Publication number Publication date
CA2959158A1 (en) 2016-03-10
CN113577074A (zh) 2021-11-02
SG11201701567UA (en) 2017-03-30
KR20210035923A (ko) 2021-04-01
AR103118A1 (es) 2017-04-19
ES2761777T3 (es) 2020-05-21
NZ729673A (en) 2023-09-29
CO2017003263A2 (es) 2017-07-28
SV2017005400A (es) 2017-04-20
EP3188599A1 (en) 2017-07-12
JO3541B1 (ar) 2020-07-05
WO2016036598A1 (en) 2016-03-10
KR20180085047A (ko) 2018-07-25
LT3188599T (lt) 2019-12-10
US20170296526A1 (en) 2017-10-19
JP2018154655A (ja) 2018-10-04
PT3188599T (pt) 2020-01-15
AP2017009772A0 (en) 2017-02-28
EP3590338A2 (en) 2020-01-08
US10278964B2 (en) 2019-05-07
PL3188599T3 (pl) 2020-06-01
CN113577073A (zh) 2021-11-02
RS59751B1 (sr) 2020-02-28
DOP2017000055A (es) 2017-08-15
TWI639429B (zh) 2018-11-01
KR102307275B1 (ko) 2021-09-30
CN107205389A (zh) 2017-09-26
JP2017526695A (ja) 2017-09-14
US9675600B2 (en) 2017-06-13
EP3590338A3 (en) 2020-03-18
MX361741B (es) 2018-12-14
JP6356907B2 (ja) 2018-07-11
PH12017500392A1 (en) 2017-07-17
TN2017000040A1 (en) 2018-07-04
EP3188599B1 (en) 2019-10-02
MD4710B1 (ro) 2020-09-30
UA120765C2 (uk) 2020-02-10
JP7044918B2 (ja) 2022-03-30
US10894041B2 (en) 2021-01-19
CL2017000494A1 (es) 2017-09-15
US20160067236A1 (en) 2016-03-10
MA40607B1 (fr) 2019-11-29
US20190175574A1 (en) 2019-06-13
UY36286A (es) 2016-02-29
US20240024303A1 (en) 2024-01-25
GEAP201814459A (en) 2018-09-10
IL250692B (en) 2019-05-30
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
EP3188599A4 (en) 2017-10-11
MD4710C1 (ro) 2021-04-30
US11723902B2 (en) 2023-08-15
AU2015312231B2 (en) 2017-10-19
CR20170121A (es) 2017-07-17
US20210093627A1 (en) 2021-04-01
PH12017500392B1 (en) 2018-08-31
KR101881264B1 (ko) 2018-07-23
KR20170047372A (ko) 2017-05-04
ME03597B (me) 2020-07-20
JP2021080281A (ja) 2021-05-27
CY1122746T1 (el) 2021-03-12
NI201700024A (es) 2017-07-18
IL250692A0 (en) 2017-04-30
HUE046894T2 (hu) 2020-04-28
MD20170025A2 (ro) 2017-07-31
AU2015312231A1 (en) 2017-03-23
BR112017003552A2 (pt) 2017-12-05
ECSP17019893A (es) 2017-05-31
HRP20192345T1 (hr) 2020-03-20
MY187167A (en) 2021-09-07
KR102234319B1 (ko) 2021-04-01
CN109172575A (zh) 2019-01-11
TW201613587A (en) 2016-04-16
PE20171109A1 (es) 2017-08-07
JP6923486B2 (ja) 2021-08-18
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
MX2017002825A (es) 2017-09-28
SI3188599T1 (sl) 2020-02-28

Similar Documents

Publication Publication Date Title
US11723902B2 (en) Medical treatments based on anamorelin
Muñoz et al. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists
Wang et al. Efficacy of oral nefopam on multimodal analgesia in total knee arthroplasty: a prospective, double-blind, placebo-controlled, randomized trial
HK40020876A (en) Medical treatments based on anamorelin
HK1234959A1 (en) Medical treatments based on anamorelin
HK1234959B (en) Medical treatments based on anamorelin
OA18229A (en) Medical treatments based on anamorelin.
NZ729673B2 (en) Medical treatments based on anamorelin
KR102481026B1 (ko) 인터루킨 23의 항체를 포함하는 화학요법유발 말초신경병증의 예방 또는 치료용 약학적 조성물
TW202327596A (zh) 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Lugano Switzerland / bazzero

Applicant after: Heersen health care Co Ltd

Address before: Lugano Switzerland / bazzero

Applicant before: Helsinn Healthcare SA

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20171124

RJ01 Rejection of invention patent application after publication